Skip to main content

Curt I. Civin, MD

Associate Dean for Research; Director, Center for Stem Cell Biology & Regenerative Medicine

Academic Title:

Professor

Primary Appointment:

Pediatrics

Secondary Appointment(s):

Physiology

Administrative Title:

Associate Dean For Research; Director, Center For Stem Cell Biology & Regenerative Medicine

Location:

BRB, 14-021; HSF II, S103D (lab)

Phone (Primary):

(410) 706-1181

Phone (Secondary):

(410) 706-1198

Education and Training

  • Amherst College, BA, Biology/Independent Study, 1966-70 (magna cum-laude)
  • Harvard Medical School, MD, 1970-74 (cum-laude)
  • Residency in Pediatrics, Boston Children’s Hospital, 1974-76
  • Fellowships, Pediatric Hematology-Oncology & Tumor-Immunology, National Cancer Institute, National Institutes of Health, 1976-79

Biosketch

Dr. Civin is a pioneer in stem cell research and cancer research who is known internationally for developing a way to isolate stem cells from other blood cells  The founding director for the University of Maryland’s Center for Stem Cell Biology & Regenerative Medicine, he has received wide recognition for his groundbreaking 1984 discovery of CD34, which has had a major impact on the field of blood research.

Dr. Civin’s breakthrough discovery of the CD34 lympho-hematopoietic stem cell antigen and monoclonal antibody accelerated basic research in stem cell and leukemia biology and improved stem cell transplantation for thousands of patients. This led to multiple honors, including the 1999 National Inventor of the Year Award and the 2009 Landsteiner Award.

Through his laboratory work, Dr. Civin accomplished the rare feat of making multiple discoveries that are used today not only in laboratory research but also in clinical bone marrow stem cell transplantation and leukemia diagnosis. His own current research focuses on targeting leukemias, on the roles of key molecules, including microRNAs and their targets in normal and leukemic stem-progenitor cells, and on applying new technologies to problems in hematology and oncology. His laboratory team has 4 decades of expertise with comprehensive studies of normal and malignant hematopoiesis using cell lines, primary human CD34+ hematopoietic stem-progenitor cells, mouse cells, and primary human leukemia cells.

Dr. Civin holds dozens of biomedical patents and is currently a principal or collaborating investigator on multiple peer-reviewed research projects funded by the National Institutes of Health, the state of Maryland, and private foundations. Dr. Civin taught and led research and clinical pediatric oncology at Johns Hopkins University School of Medicine for 30 years before becoming founding director for the University of Maryland’s Center for Stem Cell Biology & Regenerative Medicine and Associate Dean for Research in 2009.

He has lectured around the world, published more than 250 articles and book chapters, received many awards, and served in leadership positions of multiple distinguished committees and editorial boards. Throughout his career, he has mentored a large number of talented scientists to pursue field-leading academic careers in translational research.

Research/Clinical Keywords

Stem Cell Biology, Regenerative Medicine, Oncology, Gene Therapy, Hematology, Cancer, Leukemia, Bone Marrow Transplantation, Hematopoietic Stem Cells, CD34

Highlighted Publications

Civin CI, Ward T, Skelley AM, Gandhi K, Peilun Lee Z, Dosier CR, D'Silva JL, Chen Y, Kim M, Moynihan J, Chen X, Aurich L, Gulnik S, Brittain GC, Recktenwald DJ, Austin RH, Sturm JC. Automated leukocyte processing by microfluidic deterministic lateral displacement. Cytometry A. 2016 Dec;89(12):1073-1083. PubMed PMID: 27875619; PubMed Central PMCID: PMC5488292.

Fox JM, Moynihan JR, Mott BT, Mazzone JR, Anders NM, Brown PA, Rudek MA, Liu JO, Arav-Boger R, Posner GH, Civin CI, Chen X. Artemisinin-derived dimer ART-838 potently inhibited human acute leukemias, persisted in vivo, and synergized with antileukemic drugs. Oncotarget. 2016 Feb 9;7(6):7268-79. PubMed PMID: 26771236; PubMed Central PMCID: PMC4872784.

Civin CI. CD34 stem cell stories and lessons from the CD34 wars: the Landsteiner Lecture 2009. Transfusion. 2010 Sep;50(9):2046-56. PubMed PMID: 20561292.

Georgantas RW 3rd, Hildreth R, Morisot S, Alder J, Liu CG, Heimfeld S, Calin GA, Croce CM, Civin CI. CD34+ hematopoietic stem-progenitor cell microRNA expression and function: a circuit diagram of differentiation control. Proc Natl Acad Sci U S A. 2007 Feb 20;104(8):2750-5. PubMed PMID: 17293455; PubMed Central PMCID: PMC1796783.

Additional Publication Citations

Campos-González R, Skelley AM, Gandhi K, Inglis DW, Sturm JC, Civin CI, Ward T. Deterministic Lateral Displacement: The Next-Generation CAR T-Cell Processing? SLAS Technol. 2018;23(4):338-351. PubMed PMID: 29361868.

Civin CI, Ward T, Skelley AM, Gandhi K, Peilun Lee Z, Dosier CR, D'Silva JL, Chen Y, Kim M, Moynihan J, Chen X, Aurich L, Gulnik S, Brittain GC, Recktenwald DJ, Austin RH, Sturm JC. Automated leukocyte processing by microfluidic deterministic lateral displacement. Cytometry A. 2016;89(12):1073-1083. PubMed PMID: 27875619; PubMed Central PMCID: PMC5488292.

Fox JM, Moynihan JR, Mott BT, Mazzone JR, Anders NM, Brown PA, Rudek MA, Liu JO, Arav-Boger R, Posner GH, Civin CI, Chen X. Artemisinin-derived dimer ART-838 potently inhibited human acute leukemias, persisted in vivo, and synergized with antileukemic drugs. Oncotarget. 2016 Feb 9;7(6):7268-79. PubMed PMID: 26771236; PubMed Central PMCID: PMC4872784.

Huang TC, Cutler J, Bharne S, Zhong J, Weinstock D, Tyner J, Gojo I, Civin C, Pandey A. Integrated analysis of CRLF2 signaling in acute lymphoblastic leukemia identifies Polo-like kinase 1 as a potential therapeutic target. Leuk Lymphoma. 2015;56(5):1524-7. PubMed PMID: 25213184; PubMed Central PMCID: PMC4420723.

Muvarak N, Kelley S, Robert C, Baer MR, Perrotti D, Gambacorti-Passerini C, Civin C, Scheibner K, Rassool FV. c-MYC Generates Repair Errors via Increased Transcription of Alternative-NHEJ Factors, LIG3 and PARP1, in Tyrosine Kinase-Activated Leukemias. Mol Cancer Res. 2015;13(4):699-712. PubMed PMID: 25828893; PubMed Central PMCID: PMC4398615.

Kim M, Tan YS, Cheng WC, Kingsbury TJ, Heimfeld S, Civin CI. MIR144 and MIR451 regulate human erythropoiesis via RAB14. Br J Haematol. 2015;168(4):583-97. PubMed PMID: 25312678; PubMed Central PMCID: PMC4314389.

Huang TC, Renuse S, Pinto S, Kumar P, Yang Y, Chaerkady R, Godsey B, Mendell JT, Halushka MK, Civin CI, Marchionni L, Pandey A. Identification of miR-145 targets through an integrated omics analysis. Mol Biosyst. 2015;11(1):197-207. PubMed PMID: 25354783; PubMed Central PMCID: PMC4352311.

Tan YS, Kim M, Kingsbury TJ, Civin CI, Cheng WC. Regulation of RAB5C is important for the growth inhibitory effects of MiR-509 in human precursor-B acute lymphoblastic leukemia. PLoS One. 2014;9(11):e111777. PubMed PMID: 25368993; PubMed Central PMCID: PMC4219775.

Heiser D, Tan YS, Kaplan I, Godsey B, Morisot S, Cheng WC, Small D, Civin CI. Correlated miR-mRNA expression signatures of mouse hematopoietic stem and progenitor cell subsets predict "Stemness" and "Myeloid" interaction networks. PLoS One. 2014;9(4):e94852. PubMed PMID: 24747944; PubMed Central PMCID: PMC3991639.

Cramer-Morales K, Nieborowska-Skorska M, Scheibner K, Padget M, Irvine DA, Sliwinski T, Haas K, Lee J, Geng H, Roy D, Slupianek A, Rassool FV, Wasik MA, Childers W, Copland M, Müschen M, Civin CI, Skorski T. Personalized synthetic lethality induced by targeting RAD52 in leukemias identified by gene mutation and expression profile. Blood. 2013;122(7):1293-304. PubMed PMID: 23836560; PubMed Central PMCID: PMC3744994.

Mott BT, He R, Chen X, Fox JM, Civin CI, Arav-Boger R, Posner GH. Artemisinin-derived dimer phosphate esters as potent anti-cytomegalovirus (anti-CMV) and anti-cancer agents: a structure-activity study. Bioorg Med Chem. 2013;21(13):3702-7. PubMed PMID: 23673218; PubMed Central PMCID: PMC3685872.

Ramalingam S, London V, Kandavelou K, Cebotaru L, Guggino W, Civin C, Chandrasegaran S. Generation and genetic engineering of human induced pluripotent stem cells using designed zinc finger nucleases. Stem Cells Dev. 2013;22(4):595-610. PubMed PMID: 22931452; PubMed Central PMCID: PMC3565436.

Cheng WC, Kingsbury TJ, Wheelan SJ, Civin CI. A simple high-throughput technology enables gain-of-function screening of human microRNAs. Biotechniques. 2013;54(2):77-86. PubMed PMID: 23384178; PubMed Central PMCID: PMC3671589.

Farrance I, Civin C. Biochemistry and signaling in stem cells, and vice versa. Biochim Biophys Acta. 2013;1830(2):2267. PubMed PMID: 23331875.

Godsey B, Heiser D, Civin C. Inferring microRNA regulation of mRNA with partially ordered samples of paired expression data and exogenous prediction algorithms. PLoS One. 2012;7(12):e51480. PubMed PMID: 23284698; PubMed Central PMCID: PMC3526609.

Scheibner KA, Teaboldt B, Hauer MC, Chen X, Cherukuri S, Guo Y, Kelley SM, Liu Z, Baer MR, Heimfeld S, Civin CI. MiR-27a functions as a tumor suppressor in acute leukemia by regulating 14-3-3θ. PLoS One. 2012;7(12):e50895. PubMed PMID: 23236401; PubMed Central PMCID: PMC3517579.

Prince OD, Langdon JM, Layman AJ, Prince IC, Sabogal M, Mak HH, Berger AE, Cheadle C, Chrest FJ, Yu Q, Andrews NC, Xue QL, Civin CI, Walston JD, Roy CN. Late stage erythroid precursor production is impaired in mice with chronic inflammation. Haematologica. 2012;97(11):1648-56. PubMed PMID: 22581006; PubMed Central PMCID: PMC3487436.

Chu SH, Heiser D, Li L, Kaplan I, Collector M, Huso D, Sharkis SJ, Civin C, Small D. FLT3-ITD knockin impairs hematopoietic stem cell quiescence/homeostasis, leading to myeloproliferative neoplasm. Cell Stem Cell. 2012;11(3):346-58. PubMed PMID: 22958930; PubMed Central PMCID: PMC3725984.

Yu D, Zhan XH, Zhao XF, Williams MS, Carey GB, Smith E, Scott D, Zhu J, Guo Y, Cherukuri S, Civin CI, Zhan X. Mice deficient in MIM expression are predisposed to lymphomagenesis. Oncogene. 2012;31(30):3561-8. PubMed PMID: 22081072; PubMed Central PMCID: PMC3350826.

Sharkis SJ, Jones RJ, Civin C, Jang YY. Pluripotent stem cell-based cancer therapy: promise and challenges. Sci Transl Med. 2012;4(127):127ps9. PubMed PMID: 22461639; PubMed Central PMCID: PMC3397797.

Zhang H, Cui Y, Voong N, Sabatino M, Stroncek DF, Morisot S, Civin CI, Wayne AS, Levine BL, Mackall CL. Activating signals dominate inhibitory signals in CD137L/IL-15 activated natural killer cells. J Immunother. 2011;34(2):187-95. PubMed PMID: 21304401; PubMed Central PMCID: PMC3128544.

Kaplan IM, Morisot S, Heiser D, Cheng WC, Kim MJ, Civin CI. Deletion of tristetraprolin caused spontaneous reactive granulopoiesis by a non-cell-autonomous mechanism without disturbing long-term hematopoietic stem cell quiescence. J Immunol. 2011;186(5):2826-34. PubMed PMID: 21270394; PubMed Central PMCID: PMC3114656.

Lebson L, Gocke A, Rosenzweig J, Alder J, Civin C, Calabresi PA, Whartenby KA. Cutting edge: The transcription factor Kruppel-like factor 4 regulates the differentiation of Th17 cells independently of RORγt. J Immunol. 2010;185(12):7161-4. PubMed PMID: 21076063; PubMed Central PMCID: PMC3071015.

Morisot S, Wayne AS, Bohana-Kashtan O, Kaplan IM, Gocke CD, Hildreth R, Stetler-Stevenson M, Walker RL, Davis S, Meltzer PS, Wheelan SJ, Brown P, Jones RJ, Shultz LD, Civin CI. High frequencies of leukemia stem cells in poor-outcome childhood precursor-B acute lymphoblastic leukemias. Leukemia. 2010;24(11):1859-66. PubMed PMID: 20739953; PubMed Central PMCID: PMC3035974.

Huang CR, Schneider AM, Lu Y, Niranjan T, Shen P, Robinson MA, Steranka JP, Valle D, Civin CI, Wang T, Wheelan SJ, Ji H, Boeke JD, Burns KH. Mobile interspersed repeats are major structural variants in the human genome. Cell. 2010;141(7):1171-82. PubMed PMID: 20602999; PubMed Central PMCID: PMC2943426.

Kandavelou K, Ramalingam S, London V, Mani M, Wu J, Alexeev V, Civin CI, Chandrasegaran S. Targeted manipulation of mammalian genomes using designed zinc finger nucleases. Biochem Biophys Res Commun. 2009;388(1):56-61. PubMed PMID: 19635463; PubMed Central PMCID: PMC2744961.

Bohana-Kashtan O, Morisot S, Hildreth R, Brayton C, Levitsky HI, Civin CI. Selective reduction of graft-versus-host disease-mediating human T cells by ex vivo treatment with soluble Fas ligand. J Immunol. 2009;183(1):696-705. Epub 2009 Jun 17. PubMed PMID: 19535642; PubMed Central PMCID: PMC3072680

Research Interests

Hematopoiesis, leukemia, cancer biology, stem cell biology, stem cell purification, stem cell transduction, stem cell gene editing

Awards and Affiliations

    • Scholar Award, Leukemia Society of America, 1984
    • Dr Frederick Stohlman Award, Leukemia Society of America, 1986
    • Member, American Society of Clinical Investigation, 1992
    • King Fahd Chair in Pediatric Oncology, Johns Hopkins University, 1993-2000
    • Kantor Family Prize for Cancer Research Excellence, 1997
    • National Inventor of the Year Award, 1999
    • Hope Award for extraordinary achievement, Leukemia Society of America, 1999
    • Herman & Walter Samuelson Chair in Cancer Research, Johns Hopkins University, 2000-2009
    • Innovator of the Year, Leukemia & Lymphoma Society of America, 2001
    • NFCR Fellow Award, National Foundation for Cancer Research, 2003-2017
    • Editor-in-Chief, Stem Cells, 2000-2007
    • America’s Top Doctors, multiple years
    • Return of the Child Award, Leukemia Lymphoma Society, (the Society’s highest honor), 2006
    • Karl Landsteiner Memorial Award & Lectureship, American Association of Blood Banks, 2009
    • The John L. Kellerman III Memorial Lecture (Keynote), Maryland Stem Cell Research Fund Annual Meeting, 2011
    • American Society of Hematology Mentor Award, 2015

Previous Positions

  • Active Staff in Oncology and Pediatrics, The Johns Hopkins Hospital, Baltimore, MD, 1979-2009
  • Assistant Professor, Associate Professor, Professor, Oncology and Pediatrics, The Johns Hopkins University School of Medicine, 1979-2009